Octopus AIM VCT 2 plc
14 June 2017
Portfolio Update
The investment portfolio of Octopus AIM VCT 2 plc (the "Company") as at 14 June 2017 is as follows (the valuations being the unaudited valuations, at bid price, as at 31 May 2017):
| Investee Company |
Sector |
Book cost (£000) |
Movement in valuation (£000) |
Fair Value (£000) |
| Breedon Group plc |
Construction & Building |
573 |
3,627 |
4,200 |
| Quixant plc |
Technology Hardware |
465 |
3,501 |
3,966 |
| Animalcare Group plc |
Pharmaceuticals & Biotech |
824 |
2,606 |
3,430 |
| GB Group plc |
Support Services |
477 |
2,631 |
3,108 |
| IDOX plc |
Software |
356 |
2,379 |
2,735 |
| Gear4music Holdings plc |
Media |
372 |
1,780 |
2,152 |
| Craneware plc |
Software |
479 |
1,537 |
2,016 |
| Learning Technologies Group plc |
Support Services |
880 |
1,008 |
1,888 |
| Brooks Macdonald Group plc |
Finance |
610 |
1,213 |
1,823 |
| Staffline Recruitment Group plc |
Support Services |
225 |
1,540 |
1,765 |
| RWS Holdings plc |
Support Services |
249 |
1,393 |
1,642 |
| Netcall plc |
Telecommunication Services |
356 |
1,081 |
1,437 |
| Adept Telecom plc |
Telecommunication Services |
502 |
716 |
1,218 |
| Ergomed plc |
Pharmaceuticals & Biotech |
960 |
228 |
1,188 |
| DP Poland plc |
Leisure & Hotels |
364 |
764 |
1,128 |
| Gooch & Housego plc |
Electronic & Electrical |
326 |
784 |
1,110 |
| Yu Group plc |
Utilities |
470 |
572 |
1,042 |
| Restore plc |
Support Services |
311 |
703 |
1,014 |
| Clinigen Group plc |
Pharmaceuticals & Biotech |
625 |
295 |
920 |
| EKF Diagnostics Holdings plc |
Health |
864 |
43 |
907 |
| Advanced Medical Solutions Group plc |
Pharmaceuticals & Biotech |
505 |
384 |
889 |
| Next Fifteen Communications Group plc |
Media |
458 |
417 |
875 |
| Vertu Motors plc |
General Retailers |
777 |
71 |
848 |
| Plastics Capital plc |
Engineering & Machinery |
485 |
346 |
831 |
| Escher Group Holdings plc |
Software |
753 |
65 |
818 |
| CityFibre plc |
Telecommunication Services |
739 |
40 |
779 |
| Brady plc |
Software |
647 |
127 |
774 |
| Omega Diagnostics Group plc |
Health |
318 |
440 |
758 |
| TLA Worldwide plc |
Media |
538 |
188 |
726 |
| Ideagen plc |
Software |
280 |
433 |
713 |
| Escape Hunt plc |
Leisure & Hotels |
659 |
0 |
659 |
| Tasty plc |
Leisure & Hotels |
336 |
311 |
647 |
| Futura Medical plc |
Pharmaceuticals & Biotech |
645 |
(23) |
622 |
| Cello Group plc |
Media |
205 |
391 |
596 |
| Judges Scientific plc |
Electronic & Electrical |
209 |
381 |
590 |
| Abcam plc |
Pharmaceuticals & Biotech |
358 |
229 |
587 |
| Cambridge Cognition Holdings plc |
Health |
400 |
171 |
571 |
| Nasstar plc |
Software |
320 |
224 |
544 |
| Velocity Composites plc |
Industrial |
533 |
0 |
533 |
| Faron Pharmaceuticals Oy |
Pharmaceuticals & Biotech |
230 |
269 |
499 |
| LoopUp Group plc |
Software |
320 |
170 |
490 |
| Gamma Communications plc |
Telecommunication Services |
326 |
161 |
487 |
| Vectura Group plc |
Pharmaceuticals & Biotech |
332 |
138 |
470 |
| Haydale Graphene Industries plc |
Chemicals |
399 |
50 |
449 |
| SQS Software Quality Systems AG |
Software |
207 |
201 |
408 |
| Mattioli Woods plc |
Finance |
101 |
289 |
390 |
| Scientific Digital Imaging plc |
Electronic & Electrical |
119 |
245 |
364 |
| Sinclair IS Pharma plc |
Pharmaceuticals & Biotech |
274 |
74 |
348 |
| Maxcyte Inc |
Pharmaceuticals & Biotech |
340 |
(19) |
321 |
| Iomart Group plc |
Software |
178 |
123 |
301 |
| Access Intelligence plc |
Software |
446 |
(72) |
374 |
| Osirium Technologies plc |
Electronic & Electrical |
500 |
(208) |
292 |
| UP Global Sourcing Holdings plc |
Household Goods & Textiles |
182 |
105 |
287 |
| WANdisco plc |
Software |
96 |
152 |
248 |
| FreeAgent Holdings plc |
Media |
185 |
46 |
231 |
| TP Group plc |
Engineering & Machinery |
452 |
(222) |
230 |
| Hasgrove plc* |
Media |
153 |
59 |
212 |
| MyCelx Technologies Corporation |
Oil Equipment |
980 |
(679) |
301 |
| Microsaic Systems plc |
Engineering & Machinery |
722 |
(534) |
188 |
| Sphere Medical Holding plc |
Health |
400 |
(219) |
181 |
| Enteq Upstream plc |
Oil Services |
687 |
(516) |
171 |
| Midatech Pharma plc |
Pharmaceuticals & Biotech |
400 |
(243) |
157 |
| Nektan Limited |
Software |
893 |
(420) |
473 |
| Oxford Pharmascience Group plc |
Pharmaceuticals & Biotech |
900 |
(765) |
135 |
| Tyratech Inc |
Chemicals |
400 |
(280) |
120 |
| Medica Group plc |
Health |
63 |
41 |
104 |
| Mears Group plc |
Support Services |
51 |
44 |
95 |
| ReNeuron Group plc |
Pharmaceuticals & Biotech |
216 |
(134) |
82 |
| Genedrive Plc |
Pharmaceuticals & Biotech |
140 |
(70) |
70 |
| Rated People Ltd* |
Software |
236 |
(178) |
58 |
| Fusionex International plc |
Software |
188 |
(132) |
56 |
| Proxama plc |
Software |
509 |
(470) |
39 |
| 1Spatial plc |
Software |
200 |
(178) |
22 |
| Work Group plc |
Support Services |
379 |
(365) |
14 |
| Bond International Software plc |
Software |
4 |
0 |
4 |
Current Liquidity Investments
| Investee Company |
Sector |
Book cost (£000) |
Movement in valuation (£000) |
Fair Value (£000) |
Money Market Funds
|
n/a |
4,420 |
6 |
4,426 |
Octopus Portfolio Manager - Conservative Capital Growth
|
n/a |
3,600 |
267 |
3,867 |
Octopus Portfolio Manager - Defensive Capital Growth
|
n/a |
3,600 |
187 |
3,787 |
Octopus UK Micro Cap Growth Fund
|
n/a |
1,100 |
296 |
1,396 |
Since 31 May 2017 there has been one follow on investment with a cost of £313,000.
Since 31 May 2017 there has been one disposal, the proceeds of which totalled £104,000 (cost £81,000).
| Unless otherwise stated, all the investments set out above : |
1. are quoted on AIM or on the London Stock Exchange Full List: |
| 2. represent equity investments except in the case of Nektan and Access Intelligence which include investment via loan stock: and |
| 3. are in portfolio companies incorporated in the UK with the exception of: |
| |
| Escher - Ireland |
| Mycelx - USA |
| SQS - Germany |
| Nektan - Gibraltar |
| Faron Pharmaceuticals Oy - Finland |
| MayCyte Inc - USA |
| |
| *Denotes private company |
As at 31 May 2017, Octopus AIM 2's portfolio of investments including current liquidity investments comprised, by value, £74.3m and the net assets of the Company were £75.6m. Octopus AIM 2's investment portfolio is in a variety of sectors and comprises 70 UK AIM-quoted companies, 2 non-AIM companies, 4 fully listed companies on the premium segment of the Official List, none listed on NASDAQ and none traded on the NEX Exchange.
For further information, please contact:
Nicola Board
Octopus Investments Limited
Tel: 0800 316 2295
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Octopus AIM VCT 2 plc via Globenewswire